oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
TRIM24 as an independent prognostic biomarker for prostate cancer
Institute of Pathology, University Hospital Schleswig-Holstein, Luebeck, Germany; Pathology of the Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Institute of Pathology, University Hospital Schleswig-Holstein, Luebeck, Germany; Pathology of the Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Department of Urology, University Hospital Schleswig-Holstein, Germany.
Department of Urology, University Hospital Schleswig-Holstein, Germany.
Show others and affiliations
2019 (English)In: Urologic Oncology, ISSN 1078-1439, E-ISSN 1873-2496, Vol. 37, no 9, article id 576.e1Article in journal (Refereed) Published
Abstract [en]

Introduction: Simply applicable biomarkers for prostate cancer patients predicting the clinical course are urgently needed. Recently, TRIM24 has been identified to promote androgen receptor signaling and to correlate with an aggressive prostate cancer phenotype. Based on these data, we proofed TRIM24 as a prognostic biomarker for risk stratification.

Materials and Methods: We performed TRIM24 immunohistochemistry on 2 independent cohorts including a total of 806 primary tumors, 26 locally advanced/recurrent tumors, 30 lymph node metastases, 30 distant metastases, and 129 benign prostatic samples from 497 patients as well as on 246 prostate needle biopsies. Expression data were correlated with clinic-pathological data including biochemical recurrence-free survival (bRFS) as endpoint.

Results: Benign samples show no or low TRIM24 expression in 94%, while tumor tissues demonstrate significant higher levels. Strongest expression is observed in advanced and metastatic tumors. In multivariate analyses, TRIM24 up-regulation on radical prostatectomy specimens correlates with shorter bRFS independent of other prognostic parameters. 5-(10-) year bRFS rates for TRIM24 negative, low, medium and high expressing tumors are 93.1(93.1)%, 75.4(68.5)%, 54.9(47.5)% and 43.1(32.3)%, respectively. Of interest, tumors diagnosed as indolent disease, TRIM24 expression stratifies patients into specific risk groups. Increased TRIM24 expression associates with higher grade group, positive nodal status and extraprostatic tumor growth. TRIM24 assessment on prostate needle biopsies taken prior to treatment decision at time of initial diagnosis significantly correlates with recurrence after surgery.

Conclusion: Using 2 large independent radical prostatectomy specimen cohorts, we found that TRIM24 expression predicts patients' risk to develop disease recurrence with high accuracy and independent from other established biomarkers. Further, this is the first study exploring TRIM24 expression on prostate needle biopsies which represents the clinically relevant tissue type on which biomarkers guide treatment decisions. Thus, we strongly suggest introducing TRIM24 evaluation in prostate needle biopsies in clinical routine as an inexpensive and simple immunohistochemical test.

Place, publisher, year, edition, pages
Elsevier, 2019. Vol. 37, no 9, article id 576.e1
Keywords [en]
Prostate cancer, TRIM24, Biomarker, Disease recurrence, Immunohistochemical test
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-76050DOI: 10.1016/j.urolonc.2019.05.006ISI: 000481583800016PubMedID: 31178279Scopus ID: 2-s2.0-85066785386OAI: oai:DiVA.org:oru-76050DiVA, id: diva2:1348695
Note

Funding Agencies:

German Research Foundation  DFG PE1179/9-1  PE1179/11-1 

University of Luebeck 

Available from: 2019-09-05 Created: 2019-09-05 Last updated: 2019-09-05Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Carlsson, JessicaSvensson, MariaAndrén, Ove

Search in DiVA

By author/editor
Carlsson, JessicaSvensson, MariaAndrén, Ove
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Urologic Oncology
Urology and NephrologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf